Novel Pipeline Activity Signals Hope in Systemic Sclerosis, as Rheumatologists Anticipate First Real Therapeutic Advances in Years
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to Spherix Global Insights EXTON, PA, November 6, 2025 – According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the treatment landscape for systemic sclerosis […]
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix Global Insights. Exton, PA., November 03, 2025 – Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key neurological conditions—Amyotrophic Lateral Sclerosis (ALS), […]
Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly approach market entry. As leading […]
Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV) leading prescribing. Exton, PA., October 29, 2025 – Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a comprehensive view of real-world management trends and competitive dynamics […]
Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights
Inaugural coverage will include multiple myeloma, myelodysplastic syndrome and B-cell malignancies (large B-cell lymphoma and chronic lymphocytic leukemia). EXTON, PA., October 15, 2025 – Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, today announced the expansion of its hematology franchise to include […]
As Roche/Genentech’s Obinutuzumab (Gazyva) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake. Exton, PA, October 2, 2025 – Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product […]
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Spherix Global Insights finds majority of specialists expect Rinvoq’s uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. EXTON, PA, September 25, 2025 – Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral […]
Patient-Led Decisions Accelerate IBD Treatment Switching, Spherix Global Insights Finds
New patient chart audit uncovers rising wave of patient-driven treatment switches in ulcerative colitis and Crohn’s disease, opening the door for brands to accelerate market share gains. Exton, PA, August 26, 2025 – Patients with inflammatory bowel disease (IBD) in the US are taking a more active role than ever before in the decision to […]
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
TNF biosimilars continue to expand, underscoring the tension between payer-driven cost pressures and pipeline-driven opportunity. EXTON, PA, August 25, 2025 – According to the latest findings from Spherix Global Insights’ Market Dynamix™: Rheumatoid Arthritis (US) 2025, the most notable near-term disruption in the RA market stems from continued TNF biosimilar adoption at the expense of […]
Which Gene Therapy Technology Wins? New Data from Spherix Global Insights Reveals Emerging Hematologist Preferences in Beta Thalassemia Care
New research from Spherix Global Insights reveal Vertex/CRISPR Therapeutics’ Casgevy holding a competitive edge over bluebird bio’s Zynteglo as preferred beta thalassemia gene therapies. EXTON, PA, August 14, 2025 — As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within the hematology […]
